YOLFTbeta
Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd

RAD · AU · Healthcare / Biotechnology

0.004AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.004
Open0.004
Day Range0.003 – 0.004
52-Week Range0.0055 – 0.039
Volume468.69K
Market Cap21.89M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta0.86
50-Day Avg0.01
200-Day Avg0.0183

About

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.

Company Details

Leadership

  • Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder & Executive Chairman · b. 1956
  • Mr. Riccardo CanevariMD, CEO & Director
  • Dr. Dimitris Voliotis M.D.Chief Medical Officer · b. 1964
  • Mr. Aaron LauritaChief Financial Officer
  • Mr. Hitesh GoelHead of Project Management
  • Mr. Nathan Jong C.A.Joint Company Secretary
  • Ms. Amritha SushilJoint Company Secretary

Financials

Income Statement

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue08.83K292.36K299.23K13.40M2.77M
Growth (%)--+3210.60%+2.35%+4378.32%-79.34%
Cost of Revenue-2.98M3.30M21.61M3.59M4.92M
Gross Profit--2.97M-3.00M-21.31M9.81M-2.15M
Gross Margin--33661.57%-1027.56%-7121.04%73.18%-77.67%
Operating Expense-16.94M37.29M25.90M47.98M66.18M
Operating Income-484.75K-19.92M-40.29M-47.21M-38.17M-68.33M
Operating Margin--225527.71%-13781.81%-15777.22%-284.87%-2468.61%
EBITDA-484.75K-18.04M-37.11M-45.38M-31.65M-68.32M
EBITDA Margin--204330.06%-12692.63%-15164.41%-236.16%-2468.35%
Net Income-485.19K-30.34M-34.61M-47.95M-36.70M-55.15M
Net Income Margin--343550.89%-11838.59%-16024.28%-273.90%-1992.46%
R&D-7.49M22.03M17.56M27.52M49.96M
R&D as % of Total Revenue-84776.54%7533.82%5868.23%205.33%1805.09%
Interest Expense09.35M86.09K642.89K65.30K112.40K
Interest Expense % of Total Revenue-105874.07%29.45%214.85%0.49%4.06%

Balance Sheet

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets33.44K83.38M74.95M72.04M86.48M60.13M
Total Liabilities158.14K20.42M29.37M44.68M43.61M37.81M
Total Equity-124.70K62.96M44.38M28.12M44.79M24.69M
Cash27.09K26.98M11.70M18.58M29.12M4.14M
Total Debt59.00K-----
Net Debt31.91K-26.98M-11.70M-18.58M-29.12M-4.14M

Cash Flow

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-32.91K-9.91M-23.20M-22.98M-36.65M-52.78M
Investing Cash Flow-28.38M-28.37M-1.53M-320.00K1.77M-5.42M
Financing Cash Flow60.00K65.11M9.22M29.88M45.43M33.37M
Capital Expenditure128.34M1.53M5052.78M
Free Cash Flow-32.91K-38.25M-24.73M-22.98M-36.65M-
FCF to OCF100.00%386.05%106.60%100.00%100.00%-

Earnings

Report DateFeb 27, 2022Aug 30, 2022Nov 30, 2022Feb 28, 2023May 31, 2023Aug 30, 2023Nov 29, 2023Feb 29, 2024Apr 15, 2024Aug 29, 2024Nov 27, 2024Feb 28, 2025May 28, 2025Sep 16, 2025Dec 3, 2025Feb 26, 2026Jun 3, 2026Jun 30, 2026
EPS Estimate0.000.000.00-0.00-0.00-0.02-0.00-0.02-0.00-0.00-0.00-0.01-0.00-0.00-0.00-0.00-0.00-0.01
EPS Actual-0.07-0.120.00-0.05-0.02-0.02-0.04-0.04-0.04-0.04-0.01-0.01-0.01-0.01-0.010.000.00-
Surprise----16566.67%-9900.00%0.00%-9900.00%-100.00%-13233.33%-9900.00%-9900.00%0.00%-9900.00%-9900.00%-9900.00%100.00%100.00%-
TimingAfter-hoursAfter-hours-Pre-market-After-hours-Pre-marketPre-market--Pre-market------

Key Statistics & Ratios

Market Cap21.89M
Enterprise Value26.50M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales1.70
Price / Book1.24
EPS-0.02
Book Value0.007
Revenue (TTM)12.87M
Gross Profit (TTM)-34.34M
EBITDA-50.25M
Profit Margin0.00%
Operating Margin-400.35%
Return on Equity-174.71%
Return on Assets-45.15%
Shares Outstanding4.38B
Shares Float3.59B
Beta0.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%